Else Nutrition

TerrAscend Reports Third Quarter 2022 Financial Results

14 November 2022

TORONTO, Nov. 14, 2022 /CNW/ - TerrAscend Corp. ("TerrAscend" or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today reported its financial results for the third quarter ending September 30, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise and are prepared under U.S. Generally Accepted Accounting principles (GAAP).

Third Quarter 2022 Financial Highlights

  • Net Revenue increased 3.4% sequentially and 36.4% year over year to $67 million.
  • Gross Profit Margin was 36.3%, compared to 35.5% in Q2 2022 and 43.7% in Q3 2021.
  • Adjusted Gross Profit Margin1 was 46.1%, compared to 47.1% in Q2 2022 and 46.1% in Q3 2021.
  • Adjusted EBITDA1 was $11.3 million, an increase of 96% sequentially and 22.8% year over year.
  • Adjusted EBITDA Margin1 was 16.9%, compared to 8.9% in Q2 2022 and 18.8% in Q3 of 2021.
  • GAAP Net Loss was $311 million, compared to net income of $14.2 million in Q2 2022. A $331 non-cash impairment charge was recorded against goodwill and intangibles for the Company's Michigan business.
  • Cashflow from Operations was positive $1.5 million, compared to negative $16.1 million in Q2 2022.
  • Cash and Cash Equivalents totaled $34.3 million as of September 30, 2022. Subsequent to the third quarter, the Company closed on a $45.5 million non-brokered senior secured term loan.

"We took decisive action to reduce our operating expenses in the quarter while still generating record sales. These factors combined to drive substantial improvement in adjusted EBITDA margins quarter over quarter and positive cash flow from operations." commented Jason Wild, Executive Chairman of TerrAscend, "Our strong brand presence is evidenced by our retail and wholesale results in New Jersey, where we have quickly established ourselves as a leading operator with three of the top ten flower SKUs, including #1. We look forward to deploying our branded strategy in Maryland and Pennsylvania when these states implement adult use." continued Wild.

Financial Summary Q3 2022 and Comparative Periods 

(in millions of U.S. Dollars)

 

Q3 2021

  

Q2 2022

  

Q3 2022

 

Revenue, net

  

49.1

   

64.8

   

67.0

 

Quarter-over-Quarter increase

  

-16.3

%

  

30.5

%

  

3.4

%

Year-over-Year increase

  

28.9

%

  

10.4

%

  

36.4

%

          

Gross profit

  

21.5

   

23.0

   

24.4

 

Gross profit margin

  

43.7

%

  

35.5

%

  

36.3

%

Adjusted gross profit1

  

22.7

   

30.5

   

30.9

 

Adjusted gross margin %

  

46.1

%

  

47.1

%

  

46.1

%

          

Share-based compensation expense

  

5.2

   

4.4

   

2.6

 

General & Administrative expense (excluding share based compensation)

  

16.1

   

29.5

   

26.7

 

% of revenue, net

  

32.8

%

  

45.5

%

  

39.8

%

          

Net income (loss)

  

55.8

   

14.2

   

(311.0)

 
          

Adjusted EBITDA1

  

9.2

   

5.8

   

11.3

 

Adjusted EBITDA % of revenue, net

  

18.8

%

  

8.9

%

  

16.9

%

          

Cash provided by (used in) operations

  

(17.9)

   

(16.1)

   

1.5

 
 

1. Adjusted Gross Profit and Adjusted Gross Profit Margin, and Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures. Please see discussion of non-GAAP measures and reconciliation to Gross Profit and Net Income (Loss), the closest comparable GAAP measures at the end of this press release.

Third Quarter 2022 Business and Operational Highlights  

  • Entered into an agreement to exclusively introduce the Cookies brand to Pennsylvania.
  • Appointed Karim Bouaziz as President of the Northeast Region.
  • Closed on the acquisition of Pinnacle in Michigan, which includes six dispenary licenses, five of which are currently operational.
  • Opened third New Jersey Apothecarium Dispensary in Lodi.
  • Opened "Cookies Corners" at all three Apothecarium locations in New Jersey.

Subsequent Events

  • Introdroduced Gage and Cookies brands in Pennsylvania.
  • Closed on a non-brokered senior secured term loan in an aggregate principal amount of approximately $45.5 million.

Third Quarter 2022 Financial Results 

Net revenue for the third quarter totaled $67 million, an increase of 3.4% sequentially and 36.4% year-over-year. The sequential growth was primarily driven by strong results in New Jersey and a partial quarter benefit from the Pinnacle acquisition, partially offset by a decline in wholesale sales in Pennsylvania and challenging retail trends in Pennsylvania and Michigan. 

Gross margin for the quarter was 36.3%, impacted by a $6 million USD write-off of inventory in Canada.  Adjusted gross margin for the quarter, excluding the inventory write-off in Canada, was 46.1% compared to 47.1% in the previous quarter, a decline of 100 basis points sequentially, driven mainly by temporary operational drags from Maryland and Canada.  The Company has now fully exited its legacy facility in Maryland and has scaled down the business in Canada such that neither of these areas are expected to be a material drag on gross margin beginning in 2023. 

General and Administrative expenses (G&A) for the quarter were reduced by $2.8 million, or almost 10%, to $26.7 million, or 39.8% of revenue, compared to $29.5 million, or 45.5% of revenue, in the second quarter.  The $26.7 million in the third quarter included $3 million of one-time items mainly related to severance and legal settlements.    The cost reductions, partly driven by a 12% reduction in the Company's workforce, are expected to generate further savings into the fourth quarter as the Company realizes a full quarter of the benefit, without the one-time costs. 

Adjusted EBITDA for the quarter was $11.3 million versus $5.8 million in the previous quarter, representing a 96% increase sequentially. Adjusted EBITDA margin improved 800 basis points to 16.9% in the third quarter from 8.9% in the second quarter, driven by operating expense reductions. 

GAAP net loss for the third quarter was $311 million compared to $14.2 million of net income for the previous quarter.  The net loss for the quarter was driven by a $331 million non-cash impairment to goodwill and intangibles of its Michigan business.   

Balance Sheet and Cash Flow

Ending cash position for the third quarter was $34.3 million.  Following the quarter end, the Company closed on a $45.5 million non-brokered debt financing. 

Cash flow from operations totaled a positive $1.5 million in the third quarter, a significant improvement versus negative cash flow from operations of $16.1 million in the second quarter, which included $9 million of taxes paid.

Capital expenditures were $3.6 million in the third quarter, primarily related to the recently completed expansion at TerrAscend's Hagerstown facility. The Company also closed on the acquisition of Pinnacle, which included a $10 million cash component.

As of November 11, 2022, there were 324 million shares outstanding including 259 million common shares, 13 million preferred shares as converted, and 52 million exchangeable shares, using the treasury method.

Conference Call

TerrAscend will host a conference call today, November 14, 2022, to discuss these results. Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Operating Officer, and Keith Stauffer, Chief Financial Officer, will host the call starting at 5:00 p.m. Eastern time. A question-and-answer session will follow management's presentation.

DATE:

Monday, November 14, 2022

TIME:

5:00 p.m. Eastern Time

WEBCAST:

Click Here

DIAL-IN NUMBER:

1-888-664-6392

CONFERENCE ID:

17993713

REPLAY:

416-764-8677 or 1-888-390-0541
Available until 12:00 midnight Eastern Time Monday, November 28, 2022

Replay Code: 993713#

Financial results and analyses are available on the Company's website (www.terrascend.com) and SEDAR (www.sedar.com).

The Canadian Securities Exchange ("CSE") has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Definition and Reconciliation of Non-GAAP Measures

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates Adjusted Gross Profit as Gross Profit adjusted for certain material non-cash items and Adjusted EBITDA as EBITDA adjusted for certain material non-cash items and certain other adjustments management believes are not reflective of the ongoing operations and performance. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The Company believes this definition is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance and other one-time or non-recurring expenses.

The table below reconciles Gross Profit and Adjusted Gross Profit for the quarters ended September 30, 2022, June 30,2022, and September 30, 2021:

 

For the Three Months Ended

 

(in millions of U.S. Dollars)

 

September 30,
2021

  

June 30,
2022

  

September 30,
2022

 

Gross profit

  

21,497

   

22,993

   

24,363

 

Add (deduct) the impact of:

         

Relief of fair value of inventory upon acquisition

  

1,163

   

549

   

415

 

Non-cash write downs of inventory

  

   

5,894

   

6,037

 

Vape recall

  

   

1,071

   

 

Facility transition costs

  

   

   

107

 

Adjusted gross profit

  

22,660

   

30,507

   

30,922

 

The table below reconciles net loss to EBITDA and Adjusted EBITDA for the quarters ended September 30, 2022, June 30, 2022, and September 30, 2021:

 

For the Three Months Ended

 
  

September 30,
2021

  

June 30,
2022

  

September 30,
2022

 
          

Net income (loss)

 

$

55,835

  

$

14,162

  

$

(310,985)

 

Add (deduct) the impact of:

         

Provision for income taxes

  

4,999

   

4,688

   

(34,033)

 

Finance expenses

  

6,351

   

9,427

   

10,092

 

Amortization and depreciation

  

4,200

   

7,046

   

7,110

 

EBITDA

  

71,385

   

35,323

   

(327,816)

 

Add (deduct) the impact of:

         

Relief of fair value of inventory upon acquisition

  

1,163

   

549

   

415

 

Non-cash write downs of inventory

  

   

5,894

   

6,037

 

Vape recall

  

   

1,071

   

 

Share-based compensation

  

5,178

   

4,463

   

2,705

 

Impairment of goodwill and intangible assets

  

   

331,242

   

331,242

 

Loss (gain) on disposal of fixed assets

  

220

   

929

   

(81)

 

Revaluation of contingent consideration

  

(338)

   

34

   

36

 

Restructuring and executive severance

  

450

   

   

1,443

 

Legal settlements

  

   

   

1,170

 

Other one-time items

  

1,365

   

924

   

1,311

 

Gain on fair value of warrants and purchase option derivative asset

  

(69,016)

   

(47,345)

   

(5,497)

 

Indemnification asset release

  

95

   

3,998

   

 

Unrealized and realized loss (gain) on investments

  

   

234

   

(231)

 

Unrealized and realized foreign exchange loss (gain)

  

(1,256)

   

(306)

   

586

 

Adjusted EBITDA

 

$

9,246

  

$

337,010

  

$

11,320

 

About TerrAscend

TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania , New Jersey , Michigan and California , licensed cultivation and processing operations in Maryland and licensed production in Canada . TerrAscend operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns several synergistic businesses and brands, including Gage Cannabis, The Apothecarium, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. For more information, visit www.terrascend.com .

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

Forward Looking Information

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company's most recently filed MD&A, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com and in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 17, 2022 and as amended on March 24, 2022.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

Unaudited Interim Condensed Consolidated Balance Sheets 
(Amounts expressed in thousands of United States dollars, except for per share amounts)

  

At

  

At

 
  

September 30, 2022

  

December 31, 2021

 

Assets

      

Current Assets

      

Cash and cash equivalents

 

$

34,288

  

$

79,642

 

Restricted cash

  

1,031

   

 

Accounts receivable, net

  

17,937

   

14,920

 

Investments

  

3,556

   

 

Inventory

  

49,391

   

42,323

 

Prepaid Expenses and other current assets

  

7,194

   

6,336

 
   

113,397

   

143,221

 

Non-Current Assets

      

Property and equipment, net

  

244,125

   

140,762

 

Deposits

  

1,455

   

1,977

 

Operating lease right of use assets

  

30,044

   

29,561

 

Intangible assets, net

  

240,503

   

168,984

 

Goodwill

  

90,326

   

90,326

 

Indemnification asset

  

   

3,969

 

Other non-current assets

  

5,638

   

3,134

 
   

612,091

   

438,713

 

Total Assets

 

$

725,488

  

$

581,934

 
       

Liabilities and Shareholders' Equity

      

Current Liabilities

      

Accounts payable and accrued liabilities

 

$

61,680

  

$

30,340

 

Deferred revenue

  

2,309

   

1,071

 

Loans payable, current

  

75,305

   

8,837

 

Contingent consideration payable, current

  

4,434

   

9,982

 

Operating lease liability, current

  

1,582

   

1,171

 

Lease obligations under finance leases, current

  

369

   

22

 

Corporate income tax payable

  

23,088

   

9,621

 

Other current liabilities

  

3,575

   

-

 
   

172,342

   

61,044

 

Non-Current Liabilities

      

Loans payable, non-current

  

172,322

   

176,306

 

Contingent consideration payable, non-current

  

1,250

   

2,553

 

Operating lease liability, non-current

  

31,058

   

30,573

 

Lease obligations under finance leases, non-current

  

4,698

   

181

 

Warrant liability

  

679

   

54,986

 

Deferred income tax liability

  

40,414

   

14,269

 

Financing obligations

  

11,408

   

 

Other long term liabilities

  

12,495

   

13,068

 
   

274,324

   

291,936

 

Total Liabilities

  

446,666

   

352,980

 

Commitments and Contingencies

      

Shareholders' Equity

      

Share Capital

      

Series A, convertible preferred stock, no par value, unlimited shares authorized; 12,658 and 13,708 shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Series B, convertible preferred stock, no par value, unlimited shares authorized; 610 and 610 shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Series C, convertible preferred stock, no par value, unlimited shares authorized; nil and 36 shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Series D, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Proportionate voting shares, no par value, unlimited shares authorized; nil and nil shares outstanding as of September 30, 2022
and December 31, 2021, respectively

  

   

 

Exchangeable shares, no par value, unlimited shares authorized; 52,395,071 and 38,890,571 shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Common stock, no par value, unlimited shares authorized; 257,860,852 and 190,930,800 shares outstanding as of
September 30, 2022 and December 31, 2021, respectively

  

   

 

Additional paid in capital

  

877,298

   

535,418

 

Accumulated other comprehensive income (loss)

  

1,694

   

2,823

 

Accumulated deficit

  

(605,336)

   

(314,654)

 

Non-controlling interest

  

5,166

   

5,367

 

Total Shareholders' Equity

  

278,822

   

228,954

 

Total Liabilities and Shareholders' Equity

 

$

725,488

  

$

581,934

 

Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss
(Amounts expressed in thousands of United States dollars, except for per share amounts)

  

For the Three Months Ended

  

For the Nine Months Ended

 
  

September 30,
2022

  

September 30,
2021

   

September 30,
2022

  

September 30,
2021

 

Revenue

 

$

67,726

  

$

50,537

   

$

183,538

  

$

169,010

 

Excise and cultivation tax

  

(701)

   

(1,398)

    

(2,050)

   

(7,794)

 

Revenue, net

  

67,025

   

49,139

    

181,488

   

161,216

 
              

Cost of Sales

  

42,662

   

27,642

    

118,992

   

69,942

 
              

Gross profit

  

24,363

   

21,497

    

62,496

   

91,274

 
              

Operating expenses:

             

General and administrative

  

29,385

   

21,320

    

85,918

   

62,462

 

Amortization and depreciation

  

3,032

   

1,947

    

8,666

   

5,664

 

Impairment of intangible assets

  

152,928

   

    

152,928

   

3,633

 

Impairment of goodwill

  

178,314

   

    

178,314

   

5,007

 

Total operating expenses

  

363,659

   

23,267

    

425,826

   

76,766

 
              

(Loss) income from operations

  

(339,296)

   

(1,770)

    

(363,330)

   

14,508

 

Other expense (income)

             

Revaluation of contingent consideration

  

36

   

(338)

    

189

   

2,652

 

Gain on fair value of warrants and purchase option derivative asset

  

(5,497)

   

(69,016)

    

(58,555)

   

(43,715)

 

Finance and other expenses

  

9,469

   

6,972

    

30,227

   

22,281

 

Transaction and restructuring costs

  

1,359

   

1,034

    

2,601

   

1,466

 

Unrealized and realized foreign exchange loss (gain)

  

586

   

(1,256)

    

636

   

4,582

 

Unrealized and realized (gain) loss on investments

  

(231)

   

    

3

   

(6,192)

 

(Loss) income before provision from income taxes

  

(345,018)

   

60,834

    

(338,431)

   

33,434

 

Provision for income taxes

  

(34,033)

   

4,999

    

(25,602)

   

21,372

 

Net (loss) income

 

$

(310,985)

  

$

55,835

   

$

(312,829)

  

$

12,062

 
              

Foreign currency translation

  

(2,758)

   

1,745

    

1,129

   

(3,469)

 

Comprehensive (loss) income

 

$

(308,227)

  

$

54,090

   

$

(313,958)

  

$

15,531

 
              

Net (loss) income attributable to:

             

Common and proportionate Shareholders of the Company

 

$

(313,212)

  

$

54,428

   

$

(316,352)

  

$

9,594

 

Non-controlling interests

  

2,227

   

1,407

    

3,523

   

2,468

 
              

Comprehensive (loss) income attributable to:

             

Common and proportionate Shareholders of the Company

 

$

(310,454)

  

$

52,683

   

$

(317,481)

  

$

13,063

 

Non-controlling interests

  

2,227

   

1,407

    

3,523

   

2,468

 
              

Net (loss) income per share, basic and diluted

             

Net (loss) income per share - basic

 

$

(1.23)

  

$

0.30

   

$

(1.32)

  

$

0.05

 

Weighted average number of outstanding common and proportionate voting shares

  

254,355,792

   

184,438,592

    

239,567,866

   

179,441,224

 

Net (loss) income per share - diluted

 

$

(1.23)

  

$

0.25

   

$

(1.32)

  

$

0.04

 

Weighted average number of outstanding common and proportionate voting shares, assuming dilution

  

254,355,792

   

214,134,641

    

239,567,866

   

214,756,569

 

Unaudited Interim Condensed Consolidated Statements of Cash Flows
(Amounts expressed in thousands of United States dollars, except for per share amounts)

 

For the Nine Months Ended

 
  

September 30, 2022

  

September 30, 2021

 

Operating activities

      

Net (loss) income

$

 

(312,829)

 

$

 

12,062

 

Adjustments to reconcile net income to net cash provided by (used in) operating activities

      

Non-cash write downs of inventory

  

14,873

   

961

 

Accretion expense

  

5,793

   

1,981

 

Depreciation of property and equipment and amortization of intangible assets

  

19,241

   

11,250

 

Amortization of operating right-of-use assets

  

1,513

   

1,289

 

Share-based compensation

  

10,524

   

13,393

 

Deferred income tax recovery

  

(44,266)

   

(682)

 

Loss on fair value of warrants and purchase option derivative

  

(58,555)

   

(43,715)

 

Revaluation of contingent consideration

  

189

   

2,652

 

Impairment of intangible assets

  

152,928

   

3,633

 

Impairment of goodwill

  

178,314

   

5,007

 

Loss on disposal of fixed assets

  

848

   

 

Release of indemnification asset

  

3,973

   

3,891

 

Forgiveness of loan principal and interest

  

   

(766)

 

Unrealized and realized foreign exchange loss

  

636

   

4,582

 

Unrealized and realized loss (gain) on investments

  

3

   

(6,192)

 

Changes in operating assets and liabilities

      

Receivables

  

4,317

   

1,144

 

Inventory

  

(1,894)

   

(10,450)

 

Prepaid expense and deposits

  

721

   

(523)

 

Deposits

  

2,340

   

(408)

 

Other assets

  

(1,522)

   

(4,214)

 

Accounts payable and accrued liabilities and other payables

  

(9,530)

   

(590)

 

Operating lease liability

  

(889)

   

3,750

 

Other liability

  

(9,627)

   

(11,394)

 

Contingent consideration payable

  

(410)

   

(14,978)

 

Corporate income tax payable

  

9,451

   

305

 

Deferred revenue

  

427

   

 

Net cash used in operating activities

  

(33,431)

   

(28,012)

 

Investing activities

      

Investment in property and equipment

  

(24,678)

   

(26,706)

 

Investment in intangible assets

  

(1,330)

   

(342)

 

Principal payments received on lease receivable

  

394

   

559

 

Distributions of earnings from associates

  

   

469

 

Deposits for property and equipment

  

(1,455)

   

(1,739)

 

Deposits for business acquisition

  

(852)

   

(25,000)

 

Payments made for land contracts

  

(888)

   

 

Net cash received on acquisition, net of cash paid

  

16,227

   

(42,736)

 

Net cash used in investing activities

  

(12,582)

   

(95,495)

 

Financing activities

      

Proceeds from options and warrants exercised

  

24,158

   

14,042

 

Loan principal paid

  

(6,088)

   

(2,250)

 

Loan amendment fee paid

  

(2,309)

   

 

Proceeds from loans payable

  

   

766

 

Cash distributions to NJ partners

  

(1,436)

   

 

Capital contributions (paid) received (to) from non-controlling interests

  

(1,237)

   

174

 

Payments of contingent consideration

  

(6,630)

   

(18,274)

 

Payments made for financing obligations

  

(921)

   

 

Proceeds from private placement, net of share issuance costs

  

   

173,477

 

Net cash provided by financing activities

  

5,537

   

167,935

 

Net (decrease) increase in cash and cash equivalents and restricted cash during the period

  

(40,476)

   

44,428

 

Net effects of foreign exchange

  

(3,847)

   

(1,016)

 

Cash and cash equivalents and restricted cash, beginning of period

  

79,642

   

59,226

 

Cash and cash equivalents and restricted cash, end of period

$

 

35,319

 

$

 

102,638

 
       

Supplemental disclosure with respect to cash flows

      

Income taxes paid

$

 

9,213

 

$

 

37,032

 

Interest paid

$

 

20,643

 

$

 

17,408

 

Lease termination fee paid

$

 

3,300

   

-

 

Non-cash transactions

      

Equity and warrant liability issued as consideration for acquisition

$

 

337,739

 

$

 

34,427

 

Promissory note issued as consideration for acquisitions

$

 

10,000

 

$

 

6,750

 

Investment in NJ Partnership

$

 

-

 

$

 

25,000

 

Shares issued for liability settlement

$

 

264

 

$

 

-

 

Accrued capital purchases

$

 

12,118

 

$

 

4,655

 

Sign Up To Get Daily Green Stock News In Your Inbox

Please review our Disclaimer and Privacy Policy before subscribing.

STOCK QUOTE

FEATURED GREEN STOCK

Hillcrest Energy Technologies

Hillcrest Energy Technologies is a clean technology company developing high value, high performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable...

CLICK TO LEARN MORE

FEATURED GREEN STOCK

Sienna Resources

Sienna Resources is at the forefront of the battery metals revolution. The company is one of the largest landholders in the prolific Clayton Valley district, which is the only lithium producing region in the United States and located just miles...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS